Review



dapta  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    MedChemExpress dapta
    Dapta, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dapta/product/MedChemExpress
    Average 92 stars, based on 3 article reviews
    dapta - by Bioz Stars, 2026-05
    92/100 stars

    Images



    Similar Products

    92
    MedChemExpress dapta
    Dapta, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dapta/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    dapta - by Bioz Stars, 2026-05
    92/100 stars
      Buy from Supplier

    93
    TargetMol ccr5 inhibitor dapta
    Ccr5 Inhibitor Dapta, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccr5 inhibitor dapta/product/TargetMol
    Average 93 stars, based on 1 article reviews
    ccr5 inhibitor dapta - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    TargetMol dapta
    Dapta, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dapta/product/TargetMol
    Average 93 stars, based on 1 article reviews
    dapta - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    92
    MedChemExpress d ala peptide t amide dapta
    PLAUR inhibitor reverses the immunosuppressive phenotype of neutrophils and attenuates tumor progression. A) Flowchart depicting the screening strategy for small‐molecule compounds targeting PLAUR. B) The affinity of 40 candidate small‐molecule compounds targeting PLAUR detected by SPR analysis. C) Schematic diagram of the predicted docking structure of <t>DAPTA</t> and PLAUR. D) Cell viability of DAPTA detected in human neutrophils. E) Western blot analysis of PLAUR, phosphorylated and non‐phosphorylated NF‐κB expression in human neutrophils treated with DMSO or DAPTA (5 µ m ). F) quantitative PCR analysis of the indicated genes in DMSO and DAPTA treatment groups ( n = 3 per group). G) Flow cytometry analysis of CD206 and CD95 expression in DMSO and DAPTA treatment groups (n = 3 per group). H) Schematic showing the treatment plan and establishment of spontaneous HCC models in mice. I) Representative images of the spontaneous tumors at the study endpoint (5 mice per group). Scale bar: 1 cm. J) The maximum tumor volume of each group at the study endpoint ( n = 5 per group). K) Kaplan‐Meier survival curves for mice ( n = 5 per group). L) Immunofluorescence staining and statistical analysis of PLAUR, F4/80 and CD8 in the indicated groups ( n = 5 per group). Scale bars: 100 µm. M,N) Flow cytometry analysis of Ly6G + CD206 + neutrophils, CD11b + F4/80 + macrophages and CD3 + CD8 + T cells in the indicated groups ( n = 5 per group). The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student's t test.
    D Ala Peptide T Amide Dapta, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d ala peptide t amide dapta/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    d ala peptide t amide dapta - by Bioz Stars, 2026-05
    92/100 stars
      Buy from Supplier

    92
    MedChemExpress d ala peptide t amide
    PLAUR inhibitor reverses the immunosuppressive phenotype of neutrophils and attenuates tumor progression. A) Flowchart depicting the screening strategy for small‐molecule compounds targeting PLAUR. B) The affinity of 40 candidate small‐molecule compounds targeting PLAUR detected by SPR analysis. C) Schematic diagram of the predicted docking structure of <t>DAPTA</t> and PLAUR. D) Cell viability of DAPTA detected in human neutrophils. E) Western blot analysis of PLAUR, phosphorylated and non‐phosphorylated NF‐κB expression in human neutrophils treated with DMSO or DAPTA (5 µ m ). F) quantitative PCR analysis of the indicated genes in DMSO and DAPTA treatment groups ( n = 3 per group). G) Flow cytometry analysis of CD206 and CD95 expression in DMSO and DAPTA treatment groups (n = 3 per group). H) Schematic showing the treatment plan and establishment of spontaneous HCC models in mice. I) Representative images of the spontaneous tumors at the study endpoint (5 mice per group). Scale bar: 1 cm. J) The maximum tumor volume of each group at the study endpoint ( n = 5 per group). K) Kaplan‐Meier survival curves for mice ( n = 5 per group). L) Immunofluorescence staining and statistical analysis of PLAUR, F4/80 and CD8 in the indicated groups ( n = 5 per group). Scale bars: 100 µm. M,N) Flow cytometry analysis of Ly6G + CD206 + neutrophils, CD11b + F4/80 + macrophages and CD3 + CD8 + T cells in the indicated groups ( n = 5 per group). The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student's t test.
    D Ala Peptide T Amide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d ala peptide t amide/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    d ala peptide t amide - by Bioz Stars, 2026-05
    92/100 stars
      Buy from Supplier

    90
    Ruixi Biotech Co d-ala-peptide t-amide (dapta)
    PLAUR inhibitor reverses the immunosuppressive phenotype of neutrophils and attenuates tumor progression. A) Flowchart depicting the screening strategy for small‐molecule compounds targeting PLAUR. B) The affinity of 40 candidate small‐molecule compounds targeting PLAUR detected by SPR analysis. C) Schematic diagram of the predicted docking structure of <t>DAPTA</t> and PLAUR. D) Cell viability of DAPTA detected in human neutrophils. E) Western blot analysis of PLAUR, phosphorylated and non‐phosphorylated NF‐κB expression in human neutrophils treated with DMSO or DAPTA (5 µ m ). F) quantitative PCR analysis of the indicated genes in DMSO and DAPTA treatment groups ( n = 3 per group). G) Flow cytometry analysis of CD206 and CD95 expression in DMSO and DAPTA treatment groups (n = 3 per group). H) Schematic showing the treatment plan and establishment of spontaneous HCC models in mice. I) Representative images of the spontaneous tumors at the study endpoint (5 mice per group). Scale bar: 1 cm. J) The maximum tumor volume of each group at the study endpoint ( n = 5 per group). K) Kaplan‐Meier survival curves for mice ( n = 5 per group). L) Immunofluorescence staining and statistical analysis of PLAUR, F4/80 and CD8 in the indicated groups ( n = 5 per group). Scale bars: 100 µm. M,N) Flow cytometry analysis of Ly6G + CD206 + neutrophils, CD11b + F4/80 + macrophages and CD3 + CD8 + T cells in the indicated groups ( n = 5 per group). The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student's t test.
    D Ala Peptide T Amide (Dapta), supplied by Ruixi Biotech Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d-ala-peptide t-amide (dapta)/product/Ruixi Biotech Co
    Average 90 stars, based on 1 article reviews
    d-ala-peptide t-amide (dapta) - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher 2-aminoterephthalic acid (dapta
    PLAUR inhibitor reverses the immunosuppressive phenotype of neutrophils and attenuates tumor progression. A) Flowchart depicting the screening strategy for small‐molecule compounds targeting PLAUR. B) The affinity of 40 candidate small‐molecule compounds targeting PLAUR detected by SPR analysis. C) Schematic diagram of the predicted docking structure of <t>DAPTA</t> and PLAUR. D) Cell viability of DAPTA detected in human neutrophils. E) Western blot analysis of PLAUR, phosphorylated and non‐phosphorylated NF‐κB expression in human neutrophils treated with DMSO or DAPTA (5 µ m ). F) quantitative PCR analysis of the indicated genes in DMSO and DAPTA treatment groups ( n = 3 per group). G) Flow cytometry analysis of CD206 and CD95 expression in DMSO and DAPTA treatment groups (n = 3 per group). H) Schematic showing the treatment plan and establishment of spontaneous HCC models in mice. I) Representative images of the spontaneous tumors at the study endpoint (5 mice per group). Scale bar: 1 cm. J) The maximum tumor volume of each group at the study endpoint ( n = 5 per group). K) Kaplan‐Meier survival curves for mice ( n = 5 per group). L) Immunofluorescence staining and statistical analysis of PLAUR, F4/80 and CD8 in the indicated groups ( n = 5 per group). Scale bars: 100 µm. M,N) Flow cytometry analysis of Ly6G + CD206 + neutrophils, CD11b + F4/80 + macrophages and CD3 + CD8 + T cells in the indicated groups ( n = 5 per group). The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student's t test.
    2 Aminoterephthalic Acid (Dapta, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/2-aminoterephthalic acid (dapta/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    2-aminoterephthalic acid (dapta - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    91
    Tocris d ala peptide t amide dapta
    PLAUR inhibitor reverses the immunosuppressive phenotype of neutrophils and attenuates tumor progression. A) Flowchart depicting the screening strategy for small‐molecule compounds targeting PLAUR. B) The affinity of 40 candidate small‐molecule compounds targeting PLAUR detected by SPR analysis. C) Schematic diagram of the predicted docking structure of <t>DAPTA</t> and PLAUR. D) Cell viability of DAPTA detected in human neutrophils. E) Western blot analysis of PLAUR, phosphorylated and non‐phosphorylated NF‐κB expression in human neutrophils treated with DMSO or DAPTA (5 µ m ). F) quantitative PCR analysis of the indicated genes in DMSO and DAPTA treatment groups ( n = 3 per group). G) Flow cytometry analysis of CD206 and CD95 expression in DMSO and DAPTA treatment groups (n = 3 per group). H) Schematic showing the treatment plan and establishment of spontaneous HCC models in mice. I) Representative images of the spontaneous tumors at the study endpoint (5 mice per group). Scale bar: 1 cm. J) The maximum tumor volume of each group at the study endpoint ( n = 5 per group). K) Kaplan‐Meier survival curves for mice ( n = 5 per group). L) Immunofluorescence staining and statistical analysis of PLAUR, F4/80 and CD8 in the indicated groups ( n = 5 per group). Scale bars: 100 µm. M,N) Flow cytometry analysis of Ly6G + CD206 + neutrophils, CD11b + F4/80 + macrophages and CD3 + CD8 + T cells in the indicated groups ( n = 5 per group). The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student's t test.
    D Ala Peptide T Amide Dapta, supplied by Tocris, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d ala peptide t amide dapta/product/Tocris
    Average 91 stars, based on 1 article reviews
    d ala peptide t amide dapta - by Bioz Stars, 2026-05
    91/100 stars
      Buy from Supplier

    90
    Cerner Corporation c-dapta
    PLAUR inhibitor reverses the immunosuppressive phenotype of neutrophils and attenuates tumor progression. A) Flowchart depicting the screening strategy for small‐molecule compounds targeting PLAUR. B) The affinity of 40 candidate small‐molecule compounds targeting PLAUR detected by SPR analysis. C) Schematic diagram of the predicted docking structure of <t>DAPTA</t> and PLAUR. D) Cell viability of DAPTA detected in human neutrophils. E) Western blot analysis of PLAUR, phosphorylated and non‐phosphorylated NF‐κB expression in human neutrophils treated with DMSO or DAPTA (5 µ m ). F) quantitative PCR analysis of the indicated genes in DMSO and DAPTA treatment groups ( n = 3 per group). G) Flow cytometry analysis of CD206 and CD95 expression in DMSO and DAPTA treatment groups (n = 3 per group). H) Schematic showing the treatment plan and establishment of spontaneous HCC models in mice. I) Representative images of the spontaneous tumors at the study endpoint (5 mice per group). Scale bar: 1 cm. J) The maximum tumor volume of each group at the study endpoint ( n = 5 per group). K) Kaplan‐Meier survival curves for mice ( n = 5 per group). L) Immunofluorescence staining and statistical analysis of PLAUR, F4/80 and CD8 in the indicated groups ( n = 5 per group). Scale bars: 100 µm. M,N) Flow cytometry analysis of Ly6G + CD206 + neutrophils, CD11b + F4/80 + macrophages and CD3 + CD8 + T cells in the indicated groups ( n = 5 per group). The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student's t test.
    C Dapta, supplied by Cerner Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c-dapta/product/Cerner Corporation
    Average 90 stars, based on 1 article reviews
    c-dapta - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    Image Search Results


    PLAUR inhibitor reverses the immunosuppressive phenotype of neutrophils and attenuates tumor progression. A) Flowchart depicting the screening strategy for small‐molecule compounds targeting PLAUR. B) The affinity of 40 candidate small‐molecule compounds targeting PLAUR detected by SPR analysis. C) Schematic diagram of the predicted docking structure of DAPTA and PLAUR. D) Cell viability of DAPTA detected in human neutrophils. E) Western blot analysis of PLAUR, phosphorylated and non‐phosphorylated NF‐κB expression in human neutrophils treated with DMSO or DAPTA (5 µ m ). F) quantitative PCR analysis of the indicated genes in DMSO and DAPTA treatment groups ( n = 3 per group). G) Flow cytometry analysis of CD206 and CD95 expression in DMSO and DAPTA treatment groups (n = 3 per group). H) Schematic showing the treatment plan and establishment of spontaneous HCC models in mice. I) Representative images of the spontaneous tumors at the study endpoint (5 mice per group). Scale bar: 1 cm. J) The maximum tumor volume of each group at the study endpoint ( n = 5 per group). K) Kaplan‐Meier survival curves for mice ( n = 5 per group). L) Immunofluorescence staining and statistical analysis of PLAUR, F4/80 and CD8 in the indicated groups ( n = 5 per group). Scale bars: 100 µm. M,N) Flow cytometry analysis of Ly6G + CD206 + neutrophils, CD11b + F4/80 + macrophages and CD3 + CD8 + T cells in the indicated groups ( n = 5 per group). The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student's t test.

    Journal: Advanced Science

    Article Title: PLAUR + Neutrophils Drive Anti‐PD‐1 Therapy Resistance in Patients with Hepatocellular Carcinoma by Shaping an Immunosuppressive Microenvironment

    doi: 10.1002/advs.202507167

    Figure Lengend Snippet: PLAUR inhibitor reverses the immunosuppressive phenotype of neutrophils and attenuates tumor progression. A) Flowchart depicting the screening strategy for small‐molecule compounds targeting PLAUR. B) The affinity of 40 candidate small‐molecule compounds targeting PLAUR detected by SPR analysis. C) Schematic diagram of the predicted docking structure of DAPTA and PLAUR. D) Cell viability of DAPTA detected in human neutrophils. E) Western blot analysis of PLAUR, phosphorylated and non‐phosphorylated NF‐κB expression in human neutrophils treated with DMSO or DAPTA (5 µ m ). F) quantitative PCR analysis of the indicated genes in DMSO and DAPTA treatment groups ( n = 3 per group). G) Flow cytometry analysis of CD206 and CD95 expression in DMSO and DAPTA treatment groups (n = 3 per group). H) Schematic showing the treatment plan and establishment of spontaneous HCC models in mice. I) Representative images of the spontaneous tumors at the study endpoint (5 mice per group). Scale bar: 1 cm. J) The maximum tumor volume of each group at the study endpoint ( n = 5 per group). K) Kaplan‐Meier survival curves for mice ( n = 5 per group). L) Immunofluorescence staining and statistical analysis of PLAUR, F4/80 and CD8 in the indicated groups ( n = 5 per group). Scale bars: 100 µm. M,N) Flow cytometry analysis of Ly6G + CD206 + neutrophils, CD11b + F4/80 + macrophages and CD3 + CD8 + T cells in the indicated groups ( n = 5 per group). The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student's t test.

    Article Snippet: For PLAUR inhibitor treatment, mice were treated intraperitoneally with D‐Ala‐peptide T‐amide (DAPTA) (MedChemExpress, 100 μg per mouse) following the schedule shown in Figures and .

    Techniques: Western Blot, Expressing, Real-time Polymerase Chain Reaction, Flow Cytometry, Immunofluorescence, Staining